Latest From Lupin Ltd.
Suanfarma acquires an API manufacturing facility in Italy to accelerate its growth in Europe, while CapsCanada relocates its headquarters as part of its growth strategy. Meanwhile, Glenmark, Aurobindo and Cipla struggle with quality issues.
Scynexis highlights enrollment exceeding expectations in Phase III VVC trials; Daré prepares to enter Phase III to treat BV.
Teva has announced a leadership change in its global operations, while Lupin has made a key appointment to focus on quality and compliance. Among other changes in leadership roles, Olainfarm has seen one of its six management board members resign.
Lamivudine combinations with zidovudine, as well as ezetimibe, bosentan and infliximab were among the drugs in the crosshairs for Australian reimbursement price cuts from 1 October.
- Controlled Release
- Generic Drugs
- Drug Delivery
- Therapeutic Areas
- Lupin Laboratories
- Parent & Subsidiaries
- Lupin Ltd.
- Senior Management
Vinita Gupta, CEO
Ramesh Swaminathan , CFO
- Contact Info
Phone: (91) 22 6640 2222
B/4 Laxmi Towers, Bandra Kurla Complex
Mumbai, 400 051
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.